S&P 500 Industrials Sector SEC Filings — March 10, 2026

10-03-2026

Lifevantage Corporation (LFVN) filed a Form S-3 shelf registration statement on March 10, 2026, to offer and sell up to $75M in aggregate of common stock, preferred stock, debt securities, warrants, or units from time to time on terms to be determined. As of March 4, 2026, the company had 12,804,772 shares of common stock outstanding at a last reported sale price of $4.91 per share, with the aggregate market value of non-affiliate shares at $65.6M based on data as of February 26, 2026. No securities were sold under General Instruction I.B.6 of Form S-3 in the prior 12 months, and proceeds would be used for general corporate purposes including working capital and potential acquisitions, though none are currently planned.

• ·Authorized capital stock: 40M shares of common stock ($0.0001 par value) and 5M shares of preferred stock ($0.0001 par value).
• ·Common stock listed on Nasdaq Capital Market under symbol 'LFVN'.
• ·Shelf limited to no more than one-third of non-affiliate market value ($75M threshold) in any 12-month period until aggregate non-affiliate market value reaches or exceeds $75M.

10-03-2026

Sturm, Ruger & Company, Inc. (RGR) filed Amendment No. 1 to its Form 8-K on March 10, 2026, to include a corrected press release issued on March 9, 2026, responding to public statements by Beretta Holding S.A. regarding its nomination of director candidates for RGR's 2026 annual meeting of stockholders. The filing is soliciting material under Rule 14a-12. No financial metrics or performance data are provided.

10-03-2026

U.S. Bancorp's 2026 Proxy Statement solicits votes for the election of 12 director nominees (reducing Board size from 13 following Andrew Cecere's retirement after 40+ years of service), an advisory vote to approve executive compensation, and ratification of Ernst & Young LLP as independent auditors for fiscal 2026. Key highlights include the creation of a new Technology Committee effective January 1, 2026, to oversee technology strategy and cybersecurity, alongside strong governance features like a Lead Independent Director and proxy access. The annual shareholder meeting is virtual on April 21, 2026, with voting deadline April 20, 2026.

• ·Annual meeting held virtually at www.virtualshareholdermeeting.com/USB2026 on April 21, 2026; voting deadline 11:59 p.m. ET April 20, 2026 (April 16, 2026 for 401(k) shares).
• ·Deadlines for 2027 director nominations and shareholder proposals detailed on page 88.
• ·Board changes: New Technology Committee (Jan 1, 2026); Risk Management Committee oversees technology/cybersecurity risks; Governance Committee now handles corporate responsibility.
• ·Corporate governance: 3/3/20/20 proxy access; 25% threshold for special meetings; no poison pill; annual Board evaluations; overboarding limits; age 72 re-nomination review.
• ·Directors prohibited from hedging/pledging company securities.

10-03-2026

Capital City Bank Group, Inc.'s DEF 14A proxy statement outlines robust cybersecurity governance, with the CISO (over 15 years experience) managing the program and reporting quarterly to the Enterprise Risk Oversight Committee and annually to the Board. The Board, which met 9 times in 2025 with 97.6% attendance, maintains a majority-independent structure (10 independent directors listed), led by Chairman/CEO William G. Smith, Jr. and Lead Independent Director Stanley W. Connally, Jr.; independent directors held 5 executive sessions. In 2025, an external firm evaluated board performance, and all directors attended the annual meeting.

• ·Directors may serve on no more than 3 other public company boards (CEO limited to 2).
• ·Majority of Board determined independent under Nasdaq rules, considering ordinary course banking services and architectural fees to BKJ.
• ·Corporate Governance and Nominating Committee engaged Bank Director for 2025 board evaluation via anonymous questionnaires.
• ·All directors attended the 2025 Annual Meeting.
• ·Resignation tender required in uncontested elections if nominee fails majority vote; Board decides within 90 days.

10-03-2026

UWM Holdings Corporation filed a Form 8-K on March 10, 2026, reporting a press release issued on March 9, 2026, under Item 7.01 Regulation FD Disclosure, with the press release furnished as Exhibit 99.1. The filing was signed by Rami Hasani, Executive Vice President and Chief Financial Officer. No specific financial or operational details from the press release are included in the filing body.

• ·Securities registered: Class A Common Stock (UWMC) on New York Stock Exchange
• ·Company address: 585 South Boulevard E., Pontiac, Michigan 48341
• ·Registrant’s telephone: (800) 981-8898

10-03-2026

Barnes & Noble Education reported fiscal Q3 2026 revenue of $515.1 million, up 11.3% YoY from $462.8 million, driven by strong 32.1% growth in BNC First Day revenues to $293.6 million and 7.2% higher gross comparable store sales; however, net income declined to $6.7 million from $17.9 million due to the absence of prior one-time gains, and Adjusted EBITDA dipped slightly to $23.6 million from $24.8 million amid gross margin timing issues. For the first nine months of FY2026, revenue increased 9.0% to $1,447.7 million, net income swung to $13.4 million from a $42.8 million loss, and Adjusted EBITDA rose 5.5% to $61.9 million. The company announced a $0.08 per share quarterly dividend starting Q1 FY2027 and a virtual Investor Day on June 25, 2026.

• ·Total debt increased to $138.4 million as of January 31, 2026 from $122.5 million as of November 1, 2025; net debt $128.3 million after $10.1 million cash.
• ·Net working capital $245.9 million as of January 31, 2026 vs. $186.2 million as of May 3, 2025.
• ·FY2026 outlook: Adjusted EBITDA $65-75 million; ~$18 million capital expenditures; FY2027 Adjusted EBITDA growth target 15-20% or more.
• ·Q3 Adjusted Free Cash Flow $(38.3) million vs. $(49.4) million prior year; first nine months $(54.3) million vs. $(160.3) million.
• ·Dividend yield approx. 3.5% at $8.80 per share.

10-03-2026

Trailblazer Merger Corp I reported a net loss of $8.3M for the year ended December 31, 2025, compared to net income of $0.28M in 2024, primarily due to a $6.2M loss on debt extinguishment and $0.2M loss on fair value changes, despite $0.94M in interest income. Total assets declined 84% YoY to $4.3M from $27.7M, driven by Trust Account reduction to $4.0M from $26.8M amid heavy redemptions of Class A shares (down to 333K shares from 2.4M). Liabilities rose to $16.2M from $7.2M with $11.0M in new convertible promissory notes, worsening stockholders' deficit to $15.9M from $6.1M, while operating costs increased 12% YoY.

• ·Class A redeemable shares at $11.76/share in 2025 (vs $11.19/share in 2024)
• ·Excise tax payable increased to $912,593 from $497,749
• ·Promissory note - related party extinguished; new convertible note $11.0M with related party
• ·Net cash used in operating activities worsened to $2.55M from $1.56M
• ·Cash paid for income taxes $1.04M in 2025 vs $0.35M in 2024

10-03-2026

Alexander & Baldwin, Inc. held a special shareholder meeting on March 9, 2026, approving all three proposals related to the Merger Agreement dated December 8, 2025, with Tropic Purchaser LLC and Tropic Merger Sub LLC. The Merger Agreement Proposal passed overwhelmingly with 57,355,918 votes for, 424,197 against, and 113,557 abstentions on a quorum of 57,893,672 shares (79.50% of 72,820,075 outstanding shares). The merger is expected to close on or about March 12, 2026, subject to conditions.

• ·Record date for Special Meeting: January 15, 2026.
• ·Definitive Proxy Statement first mailed to shareholders on or about January 23, 2026.
• ·No broker non-votes occurred as proposals were non-routine.
• ·No other business came before the Special Meeting.

10-03-2026

Guided Therapeutics, Inc. completed a Warrant Exchange on March 2, 2026, for eligible warrants from its September 1, 2022 Private Offering, with 4,825,000 warrant shares (22.7% of outstanding eligible warrants) tendered, resulting in $980,000 cash proceeds and issuance of 4,825,000 restricted common shares. Shares outstanding increased from 86,691,976 to 91,516,976, representing about 5.6% dilution. However, participation was low, leaving 16,398,080 eligible warrants outstanding, with expirations in 2026 and 2027.

• ·Eligible warrants originally priced at $0.65 exchanged at $0.25; those at $0.50 at $0.20.
• ·Expiration of Warrant Exchange: February 25, 2026 at 8:00 a.m. ET.
• ·Offer to Exchange dated February 11, 2026.
• ·Of remaining warrants: 11,973,080 expire Sep 1-Oct 18, 2026; 4,425,000 expire Sep 1-Oct 18, 2027.
• ·Shares issued in reliance on Section 3(a)(9) exemption; no commissions paid.

10-03-2026

M&T Bank Corporation issued a DEFA14A notice for its 2026 Annual Meeting of Shareholders, to be held virtually on April 21, 2026, at 11:00 a.m. Eastern Time. Shareholders will vote on electing 12 directors for one-year terms, advisory approval of 2025 named executive officer compensation, amendment and restatement of the 2019 Equity Incentive Compensation Plan, and ratification of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026. Proxy materials are available online at envisionreports.com/MTB, with requests for paper copies needed at least 10 days prior to the meeting.

• ·Virtual meeting URL: meetnow.global/MVLYTF9
• ·Proxy request methods: Internet at envisionreports.com/MTB, phone 1-866-641-4276, or email to investorvote@computershare.com
• ·Board recommends vote FOR all director nominees, Proposal 2, Proposal 3, and Proposal 4

10-03-2026

Howmet Aerospace Inc. posted its Technology and Markets Day presentation to its website on March 10, 2026, disclosed via Form 8-K under Item 7.01 Regulation FD Disclosure. The presentation is attached as Exhibit 99.1. The information is not deemed 'filed' for purposes of Section 18 of the Exchange Act or subject to liability.

10-03-2026

Passage Bio, Inc. terminated its 15-year lease for approximately 62,000 square feet of laboratory space with Hopewell Campus Owner LLC, effective March 4, 2026, following a January 2025 restructuring that ceased operations at the site. The termination required a $4.8M fee plus accrued rent through February 14, 2026, representing a near-term cash outflow. However, the company expects its cash and cash equivalents to fund operations through Q1 2027.

• ·Original Hopewell Lease dated December 15, 2020, with 15-year term from March 2021 commencement.
• ·Lease termination agreement executed March 4, 2026; 8-K filed March 10, 2026.

10-03-2026

Opus Genetics reported FY 2025 financial results with revenue increasing 29% YoY to $14.2M from $11.0M, driven by Viatris collaboration, and a narrowed net loss of $49.6M ($0.80/share) versus $57.5M ($2.15/share) in 2024, primarily due to no repeat of a $28M IPR&D charge. However, R&D expenses rose 15% to $30.8M and G&A expenses increased 21% to $22.0M amid pipeline advancement. Cash stood at $45.1M as of Dec 31, 2025, bolstered by $25M raised post-year end for a $70.1M runway into H1 2028, alongside positive early BEST1 data and upcoming catalysts like PDUFA in Oct 2026.

• ·FDA PDUFA date of October 17, 2026 for Phentolamine Ophthalmic Solution 0.75% sNDA in presbyopia.
• ·Three-month results from full Cohort 1 of OPGx-BEST1 expected mid-2026.
• ·LYNX-3 Phase 3 topline results expected H1 2026.
• ·Phase 1/2 six-month pediatric cohort data for OPGx-LCA5 at ARVO May 2026.
• ·Total assets $50.2M as of Dec 31, 2025 (up from $36.9M in 2024).

10-03-2026

ABM reported fiscal Q1 2026 revenue of $2.2B, up 6.1% YoY including 5.5% organic growth, driven by ATS (+14%), Aviation (+10%), M&D (+7%), B&I (+4%), and Education (+2%). However, net income fell to $38.8M ($0.64/share) from $43.6M ($0.69/share), adjusted EBITDA declined to $117.8M from $120.6M, and segment operating margin dropped to 7.1% from 7.6%, mainly due to ATS project timing and service mix issues. Operating cash flow improved sharply to $62.0M from a $106.2M use, free cash flow turned positive at $48.9M, and the company repurchased $91.1M in shares.

• ·Company repurchased 2.1M shares at average $44.13/share; $92M remains available under repurchase program.
• ·Total leverage ratio 2.9x; closed WGNSTAR acquisition at start of Q2 FY2026.
• ·Board declared $0.29/share dividend payable May 4, 2026 to shareholders of record April 2, 2026.
• ·FY2026 outlook unchanged: organic revenue growth 3-4%, total revenue growth 4-5%, segment operating margin 7.8-8.0%, adjusted EPS $3.85-$4.15.
• ·Over $8B in annual revenue.

10-03-2026

VALHI INC's Chemicals Segment reported an operating loss of $24.5 million in 2025, a sharp decline from operating income of $138.5 million in 2024. The company faced multiple non-cash deferred income tax expenses, including $19.3 million due to German tax rate reductions and an additional $8.5 million valuation allowance. Sales volumes were geographically concentrated in Europe (45%) and North America (40%), with end-use primarily in coatings (59%) and plastics (30%).

• ·Loss of $0.45 per share from non-cash deferred tax expense due to German tax rate reduction in Q3 2025.
• ·Loss of $0.20 per share from valuation allowance on German deferred tax asset in Q4 2025.
• ·Loss of $0.38 per share from non-cash deferred tax expense on currency translation gains/losses in Q4 2025.

10-03-2026

On March 10, 2026, Patriot National Bancorp, Inc. posted a presentation on its Investor Relations website containing certain Q4 2025 financial information for its wholly owned subsidiary, Patriot Bank, National Association. The disclosure is furnished under Regulation FD (Item 7.01) and includes Exhibit 99.1, but is not deemed 'filed' for purposes of Section 18 of the Exchange Act. No specific financial metrics, period-over-period changes, or performance details were disclosed in the filing text.

• ·Filing applies to Common Stock, par value $0.01 per share (PNBK) on NASDAQ Global Market
• ·Information furnished as Exhibit 99.1 (Presentation)
• ·Not an emerging growth company

10-03-2026

The Clorox Company entered into a 364-day revolving credit agreement dated March 6, 2026, with banks including JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association as administrative agents, to support its acquisition of GOJO Industries, Inc. The acquisition is governed by a Membership Interest Purchase Agreement dated January 17, 2026. No specific commitment amounts or pricing details are provided in the filing excerpt.

• ·Filing date: March 10, 2026
• ·Credit agreement maturity: 364 days from March 6, 2026
• ·SEC items reported: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits)

10-03-2026

Bank of Marin Bancorp (Nasdaq: BMRC), parent of Bank of Marin, announced that President and CEO Tim Myers and EVP and CFO David Bonaccorso will participate in the Stephens Virtual West Coast Bank Trip on March 11, 2026. A copy of the presentation will be available on the company's website under Investor Relations on March 10, 2026, furnished as Exhibit 99.1.

• ·Presentation available at http://www.bankofmarin.com under “Investor Relations/News & Market Data/Presentations”

10-03-2026

Reliance Global Group, Inc. reported a net loss of $7.0M for the year ended December 31, 2025, an improvement of 23% YoY from $9.1M in 2024, primarily due to a $3.2M gain on the sale of businesses including Fortman Insurance Services (FIS), Employee Benefits Solutions (EBS), and U.S. Benefits Alliance (USBA). However, commission income declined 12% YoY to $12.4M amid these portfolio realignments, loss from operations worsened 17% to $9.0M, total operating expenses were nearly flat at a 1% decrease to $21.4M, and AEBITDA deteriorated sharply 397% to $(1.6M). Cash flows showed a net increase of $0.9M, reversing a $0.9M decrease in 2024, supported by $5.3M from investing activities.

• ·Salaries and wages increased 43% YoY to $10.3M, driven by non-cash share-based compensation.
• ·Equity-based compensation totaled $5.7M in 2025, up significantly from $0.9M in 2024.
• ·Net cash used in operating activities increased to $3.1M from $2.5M YoY.
• ·Asset sales contributed to $5.3M net cash from investing activities in 2025.

10-03-2026

WM Technology, Inc. appointed Nicholas Rellas as a Class III director effective March 5, 2026, until the 2027 annual meeting of stockholders or until his successor is qualified. The Board determined Mr. Rellas to be an independent director under Nasdaq rules, with no arrangements or understandings regarding his selection and no reportable transactions under Item 404(a) of Regulation S-K. In connection with the appointment, he received an initial grant of restricted stock units valued at approximately $400,000, vesting in three equal annual installments.

• ·Appointment recommended by Nominating and Corporate Governance Committee.
• ·Compensation pursuant to Amended Non-Employee Director Compensation Policy.
• ·Standard indemnification agreement entered with Mr. Rellas.

10-03-2026

Artisan Partners Asset Management Inc. filed an 8-K on March 10, 2026, disclosing a press release with preliminary assets under management (AUM) as of February 28, 2026. No specific AUM figures or period-over-period comparisons were detailed in the filing body.

• ·Filing includes Exhibit 99.1: Press Release dated March 10, 2026.
• ·Securities: Class A common stock (APAM) on New York Stock Exchange.

10-03-2026

Invesco Mortgage Capital Inc. (NYSE: IVR) appointed Stephanie J. Larosiliere, a veteran fixed income expert with over two decades of experience and current Head of Business Strategy and Development for Invesco Ltd. Fixed Income in North America & APAC, to its Board of Directors as an executive director, effective March 6, 2026. The appointment is intended to strengthen stockholder engagement, alignment, and institutional investor relations. Don Liu, Chair of the Board, emphasized her expertise in fixed income markets and ability to identify emerging trends.

• ·Company is a real estate investment trust externally managed by Invesco Advisers, Inc.
• ·Investor Relations Contact: Gregory Seals, 404-439-3323
• ·Website: www.invescomortgagecapital.com

10-03-2026

Equity Bancshares Inc reported net income of $22.7M for 2025, down 64% YoY from $62.6M in 2024, primarily due to a $53.2M net loss on securities transactions, higher merger expenses of $8.1M, and elevated other non-interest expenses at $165.3M (up 18%). However, net interest income grew 21% YoY to $226.1M supported by 20% loan growth to $4.20B gross and total assets expanding 19% to $6.37B, with NIM improving to 4.33% from 3.98%. ROAA declined sharply to 0.40% from 1.23%, while capital ratios remained solid with Total Risk Based Capital at 16.31%.

• ·Shares outstanding: 20,992,139 Class A as of February 27, 2026.
• ·Equity compensation plans: Weighted average exercise price $30.07 for 458,133 options.
• ·Core diluted EPS flat at $4.39 in 2025 vs $4.43 in 2024.
• ·Tier 1 Leverage Ratio declined to 10.64% from 11.67%.
• ·Book value per share $38.64 at Dec 31, 2025 (up from $34.04).

10-03-2026

LeonaBio, Inc. filed an amendment to its definitive proxy statement (DEFR14A) on March 10, 2026, for its Special Meeting of Stockholders scheduled for March 18, 2026, at 8:00 a.m. Pacific Time. The amendment clarifies that Proposal 6 is now classified as a 'routine' proposal, allowing brokers or nominees to vote at their discretion without specific shareholder instructions, thus eliminating expected broker non-votes on that item. No other changes were made to the original proxy statement filed on February 23, 2026.

• ·Amendment supersedes conflicting information in original proxy
• ·No changes to voting standards or effects of broker non-votes on other proposals

10-03-2026

Shoulder Innovations, Inc. reported net revenue growth of 49.6% YoY to $47.3M for the year ended December 31, 2025, from $31.6M in 2024, with gross profit increasing 48.7% to $36.2M. However, operating expenses rose 60.3% to $62.5M, driven by SG&A up 58.7% and R&D up 72.2%, resulting in an operating loss widening 79.5% to $26.3M and net loss expanding 158.4% to $40.4M. The company completed an IPO, boosting total assets to $170M and converting to positive stockholders' equity of $140.8M, though cash used in operating activities more than doubled to $28.6M.

• ·Adjusted EBITDA loss widened to $(36.1M) from $(11.4M).
• ·Cash increased to $26.9M from $6.1M, driven by $145.0M financing inflows including IPO net proceeds of $64.2M.
• ·Inventories grew to $21.6M from $14.0M; accounts receivable to $8.3M from $5.1M.
• ·Long-term debt steady at ~$14.9M.

10-03-2026

On March 10, 2026, the underwriters of GalaxyEdge Acquisition Corp.'s IPO fully exercised their over-allotment option, purchasing 1,500,000 additional units at $10.00 per unit for additional gross proceeds of $15 million. This increased total IPO units to 11,500,000 and aggregate gross proceeds to $115 million. A press release announcing the exercise is attached as Exhibit 99.1.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 1185 Avenue of the Americas, Suite 349, New York, NY 10036.

10-03-2026

Acura Pharmaceuticals, Inc. amended the loan schedule to its Secured Promissory Note originally dated November 10, 2022, with Abuse Deterrent Pharma, LLC, incorporating additional loans #1-#50 totaling $7.075M from December 22, 2022, to December 31, 2025, for an aggregated principal of $9.394M prior to recent additions. Loans #51-#55, each $100,000 and dated January 2 to March 9, 2026, increased the total principal to $9.894M. The amendment was executed on March 9, 2026, by Robert A. Seiser, Senior Vice President & CFO.

• ·Loan #51 dated 1/02/2026: $100,000 (total $9,494,279)
• ·Loan #52 dated 1/16/2026: $100,000 (total $9,594,279)
• ·Loan #53 dated 2/06/2026: $100,000 (total $9,694,279)
• ·Loan #54 dated 2/13/2026: $100,000 (total $9,794,279)
• ·Loan #55 dated 3/09/2026: $100,000 (total $9,894,279)

10-03-2026

Natural Grocers by Vitamin Cottage, Inc. (NGVC) held its 2026 annual meeting of stockholders virtually on March 4, 2026, with 21,267,524 shares represented, constituting 92.33% of outstanding shares. Stockholders elected Zephyr Isely, David Rooney, and Sandra Buffa as Class II directors for a three-year term, with For votes ranging from 16.0M to 17.5M shares and broker non-votes of 1.7M. Proposal No. 2 to ratify KPMG LLP as independent auditor for FY ending September 30, 2026, passed overwhelmingly with 21.1M For votes.

• ·Director votes - Zephyr Isely: For 16,026,727; Withheld 3,521,239
• ·Director votes - David Rooney: For 16,760,662; Withheld 2,787,304
• ·Director votes - Sandra Buffa: For 17,466,551; Withheld 2,081,415
• ·KPMG ratification: Against 131,811; Abstain 63,919

10-03-2026

Udemy announced that both Udemy and Coursera will hold special shareholder meetings on April 9, 2026, to vote on their planned business combination, with Udemy requiring majority shareholder approval. Vested Udemy stockholders as of the March 6, 2026 record date will receive voting instructions from their bank or broker. The internal communication reassures employees of no changes to roles or operations while highlighting substantial risks and uncertainties in the transaction, including integration challenges and regulatory approvals.

• ·Registration statement on Form S-4 filed February 25, 2026 (No. 293728)
• ·Udemy 10-K filed February 19, 2026
• ·Coursera 10-K filed February 23, 2026
• ·Definitive joint proxy statement/prospectus mailed around March 10, 2026

10-03-2026

Vanda Pharmaceuticals Inc. CEO Mihael Polymeropoulos disclosed on Fox Business that NEREUS™, recently FDA-approved for preventing motion-induced vomiting, will launch in the next couple of months with discussions on pricing and commercial strategy. The company is developing NEREUSRX™, a direct-to-consumer channel for accessing NEREUS™. No financial metrics or performance comparisons were provided.

• ·NEREUS™ FDA-approved for prevention of vomiting induced by motion
• ·Full interview available at: https://www.foxbusiness.com/video/6390680373112

10-03-2026

Edible Garden AG Incorporated entered into exchange agreements with Streeterville Capital, LLC on February 9, March 4, March 9, and March 10, 2026, exchanging a total of 480 shares of Series B Preferred Stock with an aggregate stated value of $480,000 for 175,165 shares of common stock. The exchanges were unregistered under Section 3(a)(9) of the Securities Act, with the number of common shares determined by dividing the stated value by the Nasdaq Minimum Price on the prior trading day. No other financial impacts or performance metrics were disclosed.

• ·Series B Preferred Stock has par value $0.0001 per share and stated value of $1,000 per share
• ·Common stock has par value $0.0001 per share
• ·Filing signed on March 10, 2026

10-03-2026

IF Bancorp, Inc. entered into a Contingent Payment Agreement with ServBanc Holdco, Inc. on March 9, 2026, allowing Iroquois Federal Savings and Loan Association to renew a $13.995M loan participation for up to 180 days after establishing a $7M specific reserve, with ServBanc funding a $5.005M contingent payment potentially distributable to IF Bancorp shareholders if the loan is sufficiently repaid. The merger, agreed on October 29, 2025, is expected to close on March 12, 2026, with cash consideration of $26.40 per share plus up to $1.51 per share from the contingent fund net of expenses; however, there is no guarantee of any contingent payment, as undistributed funds revert to ServBanc.

• ·Merger Agreement dated October 29, 2025
• ·Renewal Period: 120 days with possible additional 60-day extension
• ·Contingent Payment Fund reflects tax-effected impact of the $7M reserve on tangible common equity
• ·Keefe Bruyette and Woods, Inc. as financial advisor

10-03-2026

Prudential Financial's Board of Directors appointed CEO Andrew Sullivan as Chairman effective March 10, 2026, succeeding Charles Lowrey, who resigned as Executive Chairman and director but will remain as a senior advisor through the end of Q2 2026 before retiring after 25 years of service. Lowrey previously served as CEO from 2018 to 2025 and Chairman from 2019 to 2025. The company reported approximately $1.6 trillion in assets under management as of December 31, 2025.

• ·Lowrey served as Executive Chairman beginning in 2025, Chief Executive Officer from 2018 to 2025, and Chairman from 2019 to 2025.
• ·Prudential has operations in the United States, Asia, Europe, and Latin America.

10-03-2026

Liberty Global Ltd. filed a Form 8-K on March 10, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing a press release dated March 10, 2026, as Exhibit 99.1. The filing contains no specific financial or operational details from the press release, which is not deemed 'filed' under Section 18 of the Exchange Act.

10-03-2026

Voyager Technologies reported net sales of $166.4M for the year ended December 31, 2025, up 15.4% YoY from $144.2M, with growth in cost-plus fee and time & materials contracts (up to $106.9M from $83.0M) and U.S. Government sales (up to $143.2M from $121.0M). However, the operating loss widened dramatically to $108.5M (124.0% worse YoY) and net loss attributable to the company reached $104.8M (68.9% worse), driven by SG&A expenses surging 87.1% to $117.1M, cost of sales up 25.0% to $136.5M, and R&D up 67.6%; firm fixed price contracts declined slightly to $59.5M from $61.2M, while commercial sales remained flat at $23.2M.

• ·No impairment losses recorded in 2025 vs. $3.6M in 2024
• ·Income tax benefit decreased to $0.4M from $1.7M (74.2% YoY)

10-03-2026

Delek US Holdings, Inc. (CIK: 0001694426), a petroleum refining company based in Brentwood, TN, filed DEFA14A additional definitive proxy soliciting materials on March 10, 2026. The filing appears in the context of recent EDGAR listings including proxy statements (DEF 14A), annual reports (10-K), and current reports (8-K), but no specific financial metrics, changes, or shareholder proposals are detailed in the provided content. No quantitative performance data or period-over-period comparisons are present.

• ·Company SIC: 2911 (Petroleum Refining)
• ·Fiscal Year End: December 31
• ·Business Address: 310 Seven Springs Way, Suite 500, Brentwood, TN 37027
• ·Phone: 615-771-6701

10-03-2026

First Guaranty Bancshares, Inc. announced via press release that its wholly-owned subsidiary, First Guaranty Bank, entered into an agreement with Armstrong Bank to sell its Texas operations, including five branches and related deposits, loans, and certain other assets. The transaction was reported on March 10, 2026, under Regulation FD Disclosure. No financial terms or impacts were disclosed in the filing.

10-03-2026

Whirlpool Corporation issued additional proxy materials for its 2026 Annual Meeting on April 21, 2026, seeking shareholder approval on the election of 12 director nominees, an advisory vote to approve executive compensation, and ratification of Ernst & Young LLP as the independent auditor for 2026. The Board recommends voting 'FOR' all proposals. No financial metrics or performance data are disclosed in these materials.

• ·Annual Meeting: April 21, 2026, 8:00 AM Central Time at 331 N. LaSalle, Chicago, IL 60654
• ·Vote deadline: April 20, 2026 11:59 PM ET (April 16, 2026 11:59 PM ET for shares in a Plan)
• ·Proxy materials request deadline: April 7, 2026
• ·Control numbers referenced: V84168-P40401, V84169-P40401

10-03-2026

Enbridge Inc reported strong 2025 performance including record adjusted EBITDA of $19.95B (up 7% YoY from 2024, in upper half of guidance) and DCF per share of $5.71 (midpoint of guidance), alongside placing $5B of secured growth capital into service and sanctioning $14B in new projects boosting backlog to $39B. The company increased its quarterly dividend by 3% to $0.97 per share ($3.88 annualized), marking the 31st consecutive annual raise, while maintaining debt-to-EBITDA within 4.5x-5.0x target and strong safety metrics above target. Executive compensation emphasized pay-for-performance with 91% at-risk for CEO and average 83% for other NEOs, resulting in PSU payouts such as $14.4M for CEO Gregory L. Ebel at 1.34x multiplier.

• ·Business unit scorecard payouts: Gas Distribution & Storage 127%, Power 136%, Central Functions 126%.
• ·Enterprise adjusted EBITDA target range $19,400M–$20,000M.
• ·Debt-to-EBITDA within target range of 4.5x to 5.0x.
• ·Credit ratings: A (low) by DBRS, BBB+ by S&P and Fitch, Baa2 by Moody’s.
• ·PSU performance conditions: DCF per share growth (45%), TSR vs peers (45%), GHG emissions intensity reduction (10%).

10-03-2026

Eaton Corporation plc terminated its unused $8B term credit agreement on March 6, 2026, with no outstanding loans or penalties, in connection with issuing new senior notes totaling $8.5B USD across U.S. tranches (3.850% 2028 Notes $1.5B, 3.950% 2029 $1.5B, 4.200% 2031 $1.5B, 4.500% 2033 $1B, 4.800% 2036 $2B, 5.450% 2056 $1B) and €1.2B Euro tranches (3.550% 2034 €600M, 4.000% 2038 €600M), yielding net proceeds of $8.436B USD and €1.192B. Proceeds are intended for general corporate purposes, including the acquisition of Boyd Thermal. No negative impacts or declines noted in the filing.

• ·U.S. Notes closed March 6, 2026; Euro Notes closed March 10, 2026.
• ·Notes guaranteed by the Company, Eaton Corp, Eaton Capital, and certain subsidiaries.
• ·Issued under indenture dated May 9, 2025, with supplements dated March 6 and 10, 2026.
• ·Redemption options available at make-whole premium (Treasury Rate +10-15 bps) prior to specified dates, then at par.

10-03-2026

Rocket Pharmaceuticals, Inc. entered into a Sales Agreement with Cantor Fitzgerald & Co. on March 10, 2026, for a Controlled Equity Offering allowing the issuance and sale of common stock shares (par value $0.01 per share) on an at-the-market basis through the agent from time to time. The offering is governed by a Form S-3 Registration Statement (File No. 333-293925) filed on March 2, 2026, and declared effective on March 10, 2026, with sales limited to the Maximum Amount based on registered, authorized, and prospectus constraints. No specific sales volume, pricing, or proceeds are detailed in the agreement.

• ·Registration Statement: Form S-3, File No. 333-293925
• ·Registration filed March 2, 2026; effective March 10, 2026
• ·Exchange: Nasdaq Global Market
• ·Sales methods: at-the-market offerings per Rule 415(a)(4), block transactions, or privately negotiated with consent